Opinion|Videos|January 10, 2025
Revumenib’s FDA Approval and Clinical Implications
Panelists discuss the FDA approval of revumenib for relapsed/refractory acute leukemia (R/R AML) with KMT2A translocation, reviewing the eligible patient population and the mechanism of action of this menin inhibitor, while exploring key findings from the AUGMENT-101 trial and how this approval may impact treatment approaches in both the R/R and broader AML settings.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Provide details of the FDA approval on November 15, 2024, for revumenib in R/R acute leukemia with KMT2A translocation.
- Briefly review the population, and which patients can be treated with this new therapy.
- Briefly discuss the mechanism of action of this menin inhibitor, revumenib.
- Briefly comment on key takeaways from AUGMENT-101 efficacy and safety data that led to FDA approval
- What aspects of revumenib’s efficacy and safety profile stand out compared with other approved agents in AML?
- How does this FDA approval impact your treatment approach for AML overall (including R/R setting)?
Advertisement
Related to this article
The top 5 OncLive TV videos of the week cover insights in multiple myeloma, melanoma, ovarian cancer, prostate cancer, and hepatocellular carcinoma.
Data from EXCALIBER-RRMM supported FDA accelerated approval of iberdomide plus daratumumab/dexamethasone in R/R multiple myeloma.
The FDA approved iberdomide-based therapy for relapsed myeloma, rejected a neuroendocrine tumor therapy, and more.
Pankit Vachhani, MD, discusses the importance of hematocrit control in the management of polycythemia vera.
Pembrolizumab plus denosumab produced a 31% ORR and 53% 6-month PFS rate in VEGFR-TKI-pretreated advanced clear cell renal cell carcinoma.
A new study suggests genomic newborn screening could identify children at risk for early cancers and enable earlier diagnosis and less toxic treatment.
The CLDN18.2/CD47 bispecific antibody spevatamig has received FDA fast track designation for advanced and metastatic biliary tract carcinoma.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Iberdomide Plus Daratumumab/Dexamethasone for R/R Myeloma
2
Dive into the Data Supporting the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
3
Five Under 5: Top Oncology Videos for the Week of 8/9
4
Zipalertinib Plus Chemotherapy Improves PFS in First-Line EGFR Exon 20 Insertion+ NSCLC
5